Trial Profile
A Phase II Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Treated With Gemcitabine Followed by Brentuximab Vedotin Maintenance
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Gemcitabine
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Acronyms TOTAL
- 09 Jan 2023 Status changed from active, no longer recruiting to completed.
- 13 Dec 2022 Results of final analysis of this study, presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 01 Dec 2022 According to a Seagen media release, data from the study will be featured at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition.